We expect results of the apact adjuvant pancreatic cancer trial to be available by the end of 2017. And the pivotal ABRAXANE (16:17) combination trials in non-small cell lung cancer and triple negative breast cancer will read out in 2018. The second quarter is always an exciting time with important congresses